Charles River Sees Opportunity in Fostering Rare Disease Collaborations

Drug discovery in the rare disease space is increasingly reliant on collaborations between patient groups, industry, and academia. Charles River Laboratories, the global contract research organization, recently held a symposium in New York City on the need for successful collaborations to advance rare disease drug discovery. Following the symposium we spoke to Patrick Sweeney, managing director of discovery sciences at Charles River, about the evolving nature of rare disease collaborations, how that’s changing the way researchers work, and why Charles River believes it can play a unique role in facilitating rare disease collaborations.